TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas

Part of paid clinical trials in Palo Alto, California.

Sponsor
Treeline Biosciences, Inc.
Study ID
NCT07082803
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • TLN-121 — DRUG
    Specified dose on specified days.
  • TLN-254 — DRUG
    Specified dose on specified days.
  • TLN-121 — DRUG
    Specified dose on specified days.

Study Details

The primary purpose of this study is to evaluate the safety, pharmacokinetics,, and preliminary anti-tumor activity of TLN-121 as a single agent and in combination with other anti-lymphoma therapies in patients with relapsed or refractory Non-Hodgkin Lymphomas

Key Dates

First listed
Jul 24, 2025
Start date
Jun 23, 2025
Status verified
Jul 2026
Primary completion
Sep 30, 2030
Completion
Nov 30, 2030

Study Design

Enrollment
180 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Single Agent
  • Experimental: Combination Treatment

Primary Outcome Measure

Number of participants experiencing adverse events (AEs) that meet protocol-defined dose-limiting toxicity (DLT) criteria following administration of TLN-121 alone or in combination with TLN-254. [ Time Frame: Up to 2 years ]

Central Contacts

Locations (7)

FacilityCityStateZIPSite coordinators
Stanford Medicine Cancer CenterPalo AltoCalifornia94304
Yeung
[email protected]
650-736-1908
The START Center for Cancer Care - MidwestGrand RapidsMichigan49546
Andrew Sochacki
[email protected]
616-389-1800
Washington University School of MedicineSt LouisMissouri63108
Amalia Dubois
[email protected]
314-273-1486
Memorial Sloan Kettering Cancer CenterNew YorkNew York10065
Steven Horwitz
[email protected]
Weill Cornell Medicine - New York Presbyterian HospitalNew YorkNew York10065
Erin Mulvey, MD
[email protected]
646-962-2064
SCRI Oncology PartnersNashvilleTennessee37203
Principal Investigator
[email protected]
615-339-0516
The University of Texas MD Anderson Cancer CenterHoustonTexas77030
Dai Chihara, Dr.
[email protected]
713-792-2860

Find similar trials in Palo Alto, CA

By research site
Stanford Medicine Cancer Center· Palo Alto, CAThe START Center for Cancer Care - Midwest· Grand Rapids, MIWashington University School of Medicine· St Louis, MOMemorial Sloan Kettering Cancer Center· New York, NYWeill Cornell Medicine - New York Presbyterian Hospital· New York, NYSCRI Oncology Partners· Nashville, TN

Related Studies